Management strategies for autoimmune pancreatitis
INTRODUCTION: Autoimmune pancreatitis (AIP) is a newly developed concept for a peculiar type of pancreatitis, and at present is recognized as a pancreatic lesion reflecting IgG4-related systemic disease. It is of utmost importance to differentiate AIP from pancreatic cancer to avoid unnecessary surgery.
AREAS COVERED: The current management strategies for AIP, including its clinical features, diagnostic criteria, clinical subtypes, steroid therapy and prognosis are discussed, based on our 66 AIP cases and papers searched in PubMed from 1992 to March 2011, using the term 'autoimmune pancreatitis'. A new clinicopathological entity, an 'IgG4-related sclerosing disease' is also mentioned.
EXPERT OPINION: AIP should be considered in the differential diagnosis in elderly male patients presented with obstructive jaundice and pancreatic mass. Steroids are a standard therapy for AIP, but their regimen including maintenance therapy should be evaluated in prospective trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Expert opinion on pharmacotherapy - 12(2011), 14 vom: 01. Okt., Seite 2149-59 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kamisawa, Terumi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9PHQ9Y1OLM |
|---|
| Anmerkungen: |
Date Completed 13.01.2012 Date Revised 31.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1517/14656566.2011.595710 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM209529598 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM209529598 | ||
| 003 | DE-627 | ||
| 005 | 20231224005940.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1517/14656566.2011.595710 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0698.xml |
| 035 | |a (DE-627)NLM209529598 | ||
| 035 | |a (NLM)21711086 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kamisawa, Terumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management strategies for autoimmune pancreatitis |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2012 | ||
| 500 | |a Date Revised 31.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Autoimmune pancreatitis (AIP) is a newly developed concept for a peculiar type of pancreatitis, and at present is recognized as a pancreatic lesion reflecting IgG4-related systemic disease. It is of utmost importance to differentiate AIP from pancreatic cancer to avoid unnecessary surgery | ||
| 520 | |a AREAS COVERED: The current management strategies for AIP, including its clinical features, diagnostic criteria, clinical subtypes, steroid therapy and prognosis are discussed, based on our 66 AIP cases and papers searched in PubMed from 1992 to March 2011, using the term 'autoimmune pancreatitis'. A new clinicopathological entity, an 'IgG4-related sclerosing disease' is also mentioned | ||
| 520 | |a EXPERT OPINION: AIP should be considered in the differential diagnosis in elderly male patients presented with obstructive jaundice and pancreatic mass. Steroids are a standard therapy for AIP, but their regimen including maintenance therapy should be evaluated in prospective trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Prednisolone |2 NLM | |
| 650 | 7 | |a 9PHQ9Y1OLM |2 NLM | |
| 700 | 1 | |a Takuma, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Hara, Seiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Tabata, Taku |e verfasserin |4 aut | |
| 700 | 1 | |a Kuruma, Sawako |e verfasserin |4 aut | |
| 700 | 1 | |a Inaba, Yoshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Gopalakrishna, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Egawa, Naoto |e verfasserin |4 aut | |
| 700 | 1 | |a Itokawa, Fumihide |e verfasserin |4 aut | |
| 700 | 1 | |a Itoi, Takao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on pharmacotherapy |d 1999 |g 12(2011), 14 vom: 01. Okt., Seite 2149-59 |w (DE-627)NLM111602130 |x 1744-7666 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2011 |g number:14 |g day:01 |g month:10 |g pages:2149-59 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1517/14656566.2011.595710 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2011 |e 14 |b 01 |c 10 |h 2149-59 | ||